CA2793612C - Dimethyl sulfoxide (dmso) formulations for treating autism - Google Patents

Dimethyl sulfoxide (dmso) formulations for treating autism Download PDF

Info

Publication number
CA2793612C
CA2793612C CA2793612A CA2793612A CA2793612C CA 2793612 C CA2793612 C CA 2793612C CA 2793612 A CA2793612 A CA 2793612A CA 2793612 A CA2793612 A CA 2793612A CA 2793612 C CA2793612 C CA 2793612C
Authority
CA
Canada
Prior art keywords
dmso
formulation
msm
disorder
oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2793612A
Other languages
English (en)
French (fr)
Other versions
CA2793612A1 (en
Inventor
Stanley Jacob
Jesse Cozean
Colette Cozean
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abela Pharmaceuticals Inc
Original Assignee
Abela Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abela Pharmaceuticals Inc filed Critical Abela Pharmaceuticals Inc
Publication of CA2793612A1 publication Critical patent/CA2793612A1/en
Application granted granted Critical
Publication of CA2793612C publication Critical patent/CA2793612C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA2793612A 2010-03-31 2011-03-31 Dimethyl sulfoxide (dmso) formulations for treating autism Active CA2793612C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31982710P 2010-03-31 2010-03-31
US61/319,827 2010-03-31
PCT/US2011/030806 WO2011123695A1 (en) 2010-03-31 2011-03-31 Dimethy sulfoxxide (dmso) formulations for treating autism

Publications (2)

Publication Number Publication Date
CA2793612A1 CA2793612A1 (en) 2011-10-06
CA2793612C true CA2793612C (en) 2019-06-25

Family

ID=44712638

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2793612A Active CA2793612C (en) 2010-03-31 2011-03-31 Dimethyl sulfoxide (dmso) formulations for treating autism

Country Status (5)

Country Link
US (3) US20130018059A1 (https=)
EP (1) EP2552200B1 (https=)
JP (1) JP5902148B2 (https=)
CA (1) CA2793612C (https=)
WO (1) WO2011123695A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1937286B1 (en) * 2005-09-12 2016-03-09 Abela Pharmaceuticals, Inc. Compositions comprising dimethyl sulfoxide (dmso)
WO2007033180A1 (en) 2005-09-12 2007-03-22 Abela Pharmaceuticals, Inc. Materials for facilitating administration of dimethyl sulfoxide (dmso) and related compounds
EP1966229B1 (en) 2005-09-12 2015-10-21 Abela Pharmaceuticals, Inc. Systems for removing dimethyl sulfoxide (dmso) or related compounds, or odors associated with same
BRPI0921494A2 (pt) * 2008-11-03 2018-10-30 Prad Reasearch And Development Ltd método de planejamento de uma operação de amostragem para uma formação subterrãnea, método de contolar uma operação de amostragem de formação subterrânea, método de controlar uma operação de perfuração para uma formação subterrãnea, e método de realizar uma amostragem durante a operação de perfuração.
WO2011053874A1 (en) 2009-10-30 2011-05-05 Tandem Abela Development Group Llc Dimethyl sulfoxide (dmso) and methylsulfonylmethane (msm) formulations to treat osteoarthritis
AU2011313814B2 (en) * 2010-10-07 2015-12-24 Eaglepharma Pty Ltd Combination therapy for the treatment of depression and other non-infectious diseases
US9682048B1 (en) 2010-10-12 2017-06-20 Gene S. Rosen Multi-component formulations for the treatment of cognitive decline including Alzheimer's disease
KR101452302B1 (ko) 2013-07-29 2014-10-22 주식회사 하이딥 터치 센서 패널
KR101681305B1 (ko) 2014-08-01 2016-12-02 주식회사 하이딥 터치 입력 장치
JP5973073B2 (ja) 2013-11-08 2016-08-23 イーライ リリー アンド カンパニー アトモキセチン溶液
KR101712346B1 (ko) 2014-09-19 2017-03-22 주식회사 하이딥 터치 입력 장치
JP6527343B2 (ja) 2014-08-01 2019-06-05 株式会社 ハイディープＨｉＤｅｅｐ Ｉｎｃ． タッチ入力装置
ES2926179T3 (es) * 2016-11-24 2022-10-24 Sigmadrugs Kutato Korlatolt Feleloessegue Tarsasag Utilización de composiciones para la conservación de órganos/tejidos
US10183053B1 (en) 2017-06-19 2019-01-22 Gene S. Rosen Multi-component formulations
US20200276200A1 (en) * 2019-02-28 2020-09-03 Clark Gerald Sullivan Treatment of cns and developmental disorders using high-dose 5-formyl-(6s)-tetrahydrofolate

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559329A (en) * 1982-09-14 1985-12-17 Herschler R J Dietary and pharmaceutical uses of methyl-sulfonylmethane and compositions comprising it
US4514421A (en) * 1979-08-30 1985-04-30 Herschler R J Dietary and pharmaceutical uses of methylsulfonylmethane and compositions comprising it
WO1994005273A1 (en) * 1992-09-04 1994-03-17 Aws Shakir Mustafa Salim Gastrointestinal compositions containing dimethylsulfone and dimethylsulfoxide
US6197746B1 (en) * 1998-05-19 2001-03-06 Repligen Corporation Method of using secretin for treating autism
US7972601B2 (en) * 2004-05-11 2011-07-05 The Regents Of The University Of California Method of promoting delivery of an antioxidant agent to a cell expression neuroligin
AU2005286943A1 (en) * 2004-09-20 2006-03-30 Mount Sinai School Of Medicine Use of memantine (NAMENDA) to treat autism, compulsivity, and impulsivity
EP1937286B1 (en) * 2005-09-12 2016-03-09 Abela Pharmaceuticals, Inc. Compositions comprising dimethyl sulfoxide (dmso)
WO2007049262A1 (en) * 2005-10-27 2007-05-03 Berand Limited Methods and compositions for the promotion of neuronal growth and the treatment of asociality and affective disorders
WO2008091704A2 (en) * 2007-01-25 2008-07-31 Georgetown University Treatment of cushing's syndrome and autism
US20090324784A1 (en) * 2008-06-26 2009-12-31 Nano Terra, Inc. Methods for reducing the sensory effects of odorous compounds
AU2010281739B2 (en) * 2009-10-30 2011-06-09 Biogenic Innovations, Llc Use of methylsulfonylmethane (MSM) to modulate microbial activity

Also Published As

Publication number Publication date
CA2793612A1 (en) 2011-10-06
US20200179306A1 (en) 2020-06-11
JP5902148B2 (ja) 2016-04-13
EP2552200B1 (en) 2015-10-14
US20130018059A1 (en) 2013-01-17
EP2552200A4 (en) 2013-08-21
EP2552200A1 (en) 2013-02-06
JP2013523769A (ja) 2013-06-17
US20230095199A1 (en) 2023-03-30
WO2011123695A1 (en) 2011-10-06
WO2011123695A8 (en) 2012-08-09

Similar Documents

Publication Publication Date Title
CA2793612C (en) Dimethyl sulfoxide (dmso) formulations for treating autism
CA2580619C (en) Use of memantine (namenda) to treat autism, compulsivity, and impulsivity
US8962042B2 (en) Methods for treating neurological disorders using nutrient compositions
US12156896B2 (en) Methods for treating neurological disorders using nutrient compositions
US10130602B2 (en) Use of L-carnitine, salts and derivatives thereof for reducing or preventing fatigue and improving cognitive function
US20140322369A1 (en) Ellagitannins Rich Extracts Composition
JP6940631B2 (ja) 安息香酸塩で自閉症スペクトラム障害を予防または治療するための方法
Connor Nadolol for self-injury, overactivity, inattention, and aggression in a child with pervasive developmental disorder
Mintz et al. Combined use of alcohol and nicotine gum
US20250041370A1 (en) Methods for Treating Neurological Disorders Using Nutrient Compositions
GLYNN et al. COMBINED USE OF ALCOHOL AND NICOTINE GUM
CN117500490A (zh) 用于治疗执行功能障碍的组合治疗
EP2508179A1 (en) Use of L-Carnitine, salts and derivatives thereof for reducing or preventing fatigue and improving cognitive function
Teferra Impact of khat on health with emphasis on mental health
Noble Testing for a “Sobering Pill”
HK1192849A (en) Use of l-carnitine, salts and derivatives thereof for reducing or preventing fatigue and improving cognitive function

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160331

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20251002

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20251106

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251107